Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 284

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

Loo, Deryk, Alderson, Ralph F., Chen, Francine Z., Huang, Ling, Zhang, Wenjun, Gorlatov, Sergey, Burke, Steve, Ciccarone, Valentina, Li, Hua, Yang, Yinhua, Son, Tom, Chen, Yan, Easton, Ann N., Li, Jonathan C., Rillema, Jill R., Licea, Monica, Fieger, Claudia, Liang, Tony W., Mather, Jennie P., Koenig, Scott, Stewart, Stanford J., Johnson, Syd, Bonvini, Ezio, Moore, Paul A.·2012·Clinical Cancer Research

Abstract

Purpose: The goal of this research was to harness a monoclonal antibody (mAb) discovery platform to identify cell-surface antigens highly expressed on cancer and develop, through Fc optimization, potent mAb therapies toward these tumor-specific antigens. Experimental Design: Fifty independent mAbs targeting the cell-surface immunoregulatory B7-H3 protein were obtained through independent intact cell-based immunizations using human tissue progenitor cells, cancer cell lines, or cell lines displaying cancer stem cell properties. Binding studies revealed this natively reactive B7-H3 mAb panel to bind a range of independent B7-H3 epitopes. Immunohistochemical analyses showed that a subset displayed strong reactivity to a broad range of human cancers while exhibiting limited binding to normal human tissues. A B7-H3 mAb displaying exquisite tumor/normal differential binding was selected for humanization and incorporation of an Fc domain modified to enhance effector-mediated antitumor function via increased affinity for the activating receptor CD16A and decreased binding to the inhibitory receptor CD32B. Results: MGA271, the resulting engineered anti–B7-H3 mAb, mediates potent antibody-dependent cellular cytotoxicity against a broad range of tumor cell types. Furthermore, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. Toxicology studies carried out in cynomolgus monkeys revealed no significant test article-related safety findings. Conclusions: This data supports evaluation of MGA271 clinical utility in B7-H3–expressing cancer, while validating a combination of a nontarget biased approach of intact cell immunizations and immunohistochemistry to identify novel cancer antigens with Fc-based mAb engineering to enable potent antitumor activity. Clin Cancer Res; 18(14); 3834–45. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-0715

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 284

Metadata

Authors
Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S., Ciccarone, V., Li, H., Yang, Y., Son, T., Chen, Y., Easton, A. N., Li, J. C., Rillema, J. R., Licea, M., Fieger, C., Liang, T. W., Mather, J. P., Koenig, S., Stewart, S. J., Johnson, S., Bonvini, E., & Moore, P. A.
Venue
Clinical Cancer Research
Published
2012-07-15
Volume
18
Issue
14
Pages
3834-3845
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2155977618
Cited by
284
References
37
FWCI
6.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-0715
The paper
Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S., Ciccarone, V., Li, H., Yang, Y., Son, T., Chen, Y., Easton, A. N., Li, J. C., Rillema, J. R., Licea, M., Fieger, C., Liang, T. W., Mather, J. P., . . . Moore, P. A. (2012). Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-0715

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.